Insulin degludec/liraglutide biosimilar (Federal Biotechnology (Zhuhai Hengqin))

The primary objective is to investigate the pharmacokinetic characteristics of degludec insulin liraglutide injection and to compare the pharmacokinetic similarity of a single subcutaneous injection of degludec insulin liraglutide (test preparation) with the original drug "NovoElix®" (reference preparation) in healthy Chinese adult subjects. The secondary objective is to evaluate the safety of degludec insulin liraglutide injection and preliminarily evaluate its immunogenicity.